This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AZRX

AzurRx BioPharma (AZRX) Stock Price, News & Analysis

AzurRx BioPharma logo

About AzurRx BioPharma Stock (NASDAQ:AZRX)

Key Stats

Today's Range
$2.05
▼
$2.22
50-Day Range
$2.40
▼
$41.00
52-Week Range
$3.36
▼
$26.30
Volume
126,966 shs
Average Volume
628,703 shs
Market Capitalization
$19.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.

Receive AZRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AzurRx BioPharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AZRX Stock News Headlines

Entero Therapeutics Inc (ENTO)
You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
FWBI First Wave BioPharma, Inc.
First Wave BioPharma Inc (FWBI)
First Wave BioPharma Inc
AzurRx BioPharma Changes Name to First Wave BioPharma
See More Headlines

AZRX Stock Analysis - Frequently Asked Questions

AzurRx BioPharma's stock reverse split before market open on Monday, September 13th 2021.The 1-10 reverse split was announced on Monday, September 13th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 13th 2021. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

AzurRx BioPharma (AZRX) raised $15 million in an initial public offering (IPO) on Friday, September 9th 2016. The company issued 2,100,000 shares at $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that AzurRx BioPharma investors own include SCYNEXIS (SCYX), NIO (NIO), Oncobiologics (OTLK), Bionano Genomics (BNGO), Marker Therapeutics (MRKR), Ocugen (OCGN) and 9 Meters Biopharma (NMTR).

Company Calendar

Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Software
Sub-Industry
Application Software
Current Symbol
NASDAQ:AZRX
CIK
1604191
Fax
N/A
Employees
12
Year Founded
2014

Profitability

EPS (Trailing Twelve Months)
($11.50)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$32.67 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-482.96%
Return on Assets
-258.47%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.33
Quick Ratio
1.33

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.76) per share
Price / Book
-2.74

Miscellaneous

Outstanding Shares
9,326,000
Free Float
8,645,000
Market Cap
$19.40 million
Optionable
Not Optionable
Beta
1.51

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:AZRX) was last updated on 4/8/2026 by MarketBeat.com Staff.
From Our Partners